Clinical trials · New York, NY
Glioblastoma clinical trials in New York
We’re tracking 34 recruiting glioblastoma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06894979RecruitingPhase 1
Adding AZD1390 to Radiation for New Brain Tumors
This trial tests adding a new drug called AZD1390 to standard radiation therapy for children and young adults with certain aggressive brain tumors. The goal is to see if the combination is safe and works better than radiation alone.
New York, New YorkAges 1–22 - NCT01269853RecruitingPhase 1/Phase 2
Bevacizumab directly into brain arteries for recurrent brain tumors
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
New York, New YorkAges 18 years+ - NCT06991101RecruitingPhase 2
Ruxolitinib with radiation and chemo for new glioblastoma
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
New York, New YorkAges 18 years+ - NCT03213002RecruitingPhase 1/Phase 2
CAPTEM pills after brain radiation for newly diagnosed glioblastoma
This trial studies whether taking two chemotherapy pills (capecitabine and temozolomide) after the initial 6-week radiation-and-chemo phase can help people with newly diagnosed glioblastoma. It aims to test safety and early effectiveness right before the usual maintenance temozolomide phase.
New York, New YorkAges 18–74 - NCT05271240RecruitingPhase 3
Targeted brain-artery drug added to standard treatment for new GBM
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
New York, New YorkAges 18 years+ - NCT06910306Recruiting
DaRT alpha radiation for recurrent glioblastoma
This trial tests a device called DaRT that delivers alpha radiation directly to a recurrent glioblastoma tumor. It may help patients who cannot have surgery and have a single, small tumor regrowth.
New York, New YorkAges 18–85 - NCT05979064Recruiting
Belly fat graft for recurrent brain tumor
This study tests if a piece of your own belly fat (omentum) placed in the brain during tumor surgery can help fight recurrent glioblastoma. It is for people who are already scheduled for surgery to remove their brain tumor.
New York, New YorkAges 18 years+ - NCT06934889RecruitingPhase 1
Study of ABBV-637 or ABBV-155 with ERAS-801 for recurrent glioblastoma
This trial tests two new drugs (ABBV-637 or ABBV-155) combined with ERAS-801 for people with recurrent glioblastoma (a type of brain cancer). It may help if your tumor has a specific genetic change (EGFR amplification) and you are having surgery to remove part of the tumor.
New York, New YorkAges 18 years+ - NCT02861898RecruitingPhase 1/Phase 2
Cetuximab delivered into the brain tumor artery for new glioblastoma
This Phase 1/2 study tests whether giving cetuximab directly into the artery that feeds the brain tumor can help people with newly diagnosed glioblastoma. It aims to target the tumor more precisely while checking safety and early signs of benefit.
New York, New YorkAges 18 years+ - NCT05954858Recruiting
Surgical flap to help treat glioblastoma by bypassing the blood-brain barrier
This trial tests a surgical technique that places a tissue flap near a glioblastoma surgery site to help medicines reach the brain more effectively. You might be considered if you are planning major brain tumor surgery and meet specific health, imaging, and lab requirements.
New York, New YorkAges 18 years+ - NCT06556563RecruitingPhase 3
Optune with chemo and immunotherapy for new glioblastoma
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
New York, New YorkAges 18 years+ - NCT06805305RecruitingPhase 2
Immunotherapy for newly diagnosed glioblastoma
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
New York, New YorkAges 18 years+ - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
New York, New YorkAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
New York, New YorkAges 18 years+ - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
New York, New YorkAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT05463848RecruitingPhase 2
Surgery plus pembrolizumab with olaparib and temozolomide for glioblastoma
This trial tests a combination treatment after surgery for people with glioblastoma that has come back once or twice. It aims to improve control of the tumor by adding immune therapy and targeted DNA-damage treatment along with chemotherapy.
New York, New YorkAges 18 years+ - NCT07225621RecruitingPhase 2
Light and sound therapy for newly diagnosed glioblastoma
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
New York, New YorkAges 18–80 - NCT07464925RecruitingPhase 1
Testing GLIX1 for adults with returning high-grade glioma
This trial tests a new drug called GLIX1 to find a safe dose for people whose high-grade glioma (a fast-growing brain tumor) has come back or is getting worse after earlier treatments. It may be an option if you've had no more than two prior treatments.
New York, New YorkAges 18 years+ - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
New York, New YorkAges 18 years+ - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
New York, New YorkAges 18 years+ - NCT06058988RecruitingPhase 2
T-DXd for people with brain cancer
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
New York, New YorkAges 18 years+ - NCT05303467RecruitingPhase 1
Safety study of a glioblastoma device for recurring tumors
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
New York, New YorkAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
New York, New YorkAges Any age
Hear when a new Glioblastoma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Glioblastoma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting glioblastoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Lenox Hill Hospital · 8 studies
- NYU Langone Health · 5 studies
- Columbia University Irving Medical Center · 4 studies
- Rutgers Cancer Institute of New Jersey · 3 studies
- Atlantic Health System · 2 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 2 studies
- Memorial Sloan Kettering Basking Ridge · 2 studies
What taking part in a glioblastoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting glioblastoma studies in New York.
Common questions
- Are there glioblastoma clinical trials near New York?
- Yes. We're currently tracking 34 recruiting glioblastoma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioblastoma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioblastoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioblastoma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.